mRNA cancer vaccines alone or with other drugs for solid tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests two experimental mRNA vaccines (mRNA-4106 and mRNA-4200) given either alone or together with other cancer treatments. The goal is to see if they are safe and work against advanced or metastatic solid tumors like melanoma, lung, liver, and colon cancer. Participation requires that you have tried or refused all standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer that other treatments have not helped or that you have decided not to treat with standard options.
- You have measurable disease (tumors that can be seen on scans or exams).
- You are physically active and able to care for yourself (ECOG performance status ≤ 1).
- You have enough bone marrow and organ function (as shown by blood tests).
- You do not have cancer that has spread to the brain or spinal cord (active CNS tumors).
- You have had no live vaccines within 30 days before the first dose and no plans for them during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial is testing an experimental mRNA vaccine (which targets a protein called circFAM53B-219aa found on tumor cells) combined with an immunotherapy drug (anti-PD-1) to treat advanced cancers that have stopped responding to standard treatments. The goal is to see if this combination is safe and effective for people with solid tumors like lung, breast, melanoma, pancreatic, and colon cancer.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.